Menu

Sun Pharma

Overview

Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It is among the largest pharmaceutical companies in India and ranks among the leading generic drug manufacturers globally. The company develops, manufactures and markets a broad range of branded and generic formulations, active pharmaceutical ingredients (APIs) and specialty products across therapy areas such as dermatology, ophthalmology, oncology, cardiology, neurology, psychiatry and gastroenterology.

Key facts

Name Sun Pharmaceutical Industries Limited
Type Public company
Industry Pharmaceuticals
Founder Dilip Shanghvi
Founded 1983, Vapi, Gujarat
Headquarters Mumbai, Maharashtra, India
Listings BSE, NSE
Country India

Background

Sun Pharma was founded in 1983 by Dilip Shanghvi in Vapi, Gujarat, initially with a small portfolio of psychiatry products. The company expanded steadily into other chronic-care therapy segments and over the following decades grew into a diversified pharmaceutical major through a combination of organic growth, in-licensing arrangements and a series of domestic and international acquisitions.

The company operates a global network of manufacturing facilities and research centres, supplying formulations and APIs to markets in India, the United States, emerging markets and Western Europe. Its specialty business focuses on innovative and differentiated branded products, particularly in dermatology and ophthalmology.

History and timeline

  • 1983: Founded by Dilip Shanghvi in Vapi, Gujarat, with five psychiatry products.
  • 1990s: Expanded into cardiology, gastroenterology and other chronic therapy areas; established additional manufacturing facilities in India.
  • 1994: Listed on Indian stock exchanges through an initial public offering.
  • 1997 onwards: Began an international expansion strategy, including the acquisition of Caraco Pharmaceutical Laboratories in the United States.
  • 2007: Demerged its innovative research activities into a separate listed entity, Sun Pharma Advanced Research Company (SPARC).
  • 2010: Acquired a controlling stake in Israel-based Taro Pharmaceutical Industries, strengthening its dermatology portfolio in the United States.
  • 2014–2015: Acquired Ranbaxy Laboratories in a share-swap transaction, becoming one of the largest generic pharmaceutical companies in the world.

Operations

Sun Pharma's operations span formulations, APIs and specialty pharmaceuticals. Its formulations business covers a wide range of dosage forms, while the API business supports both captive consumption and external sales. The specialty segment markets branded innovative products primarily in the United States and select global markets.

The company maintains manufacturing plants across multiple Indian states, including Gujarat, Maharashtra, Madhya Pradesh, Himachal Pradesh, Sikkim and Jammu & Kashmir, along with international sites in countries such as the United States, Israel, Hungary, Romania, Canada, Bangladesh and others acquired through global expansion.

Research and development

Sun Pharma operates research centres in India and overseas, focusing on generic product development, complex generics, novel drug delivery systems and specialty products. Innovative new chemical entity research is largely housed under its sister company, Sun Pharma Advanced Research Company (SPARC), which was demerged from the parent in 2007.

Leadership

Dilip Shanghvi serves as the Managing Director and continues to be the company's largest shareholder through promoter holdings. The board includes a mix of executive and independent directors overseeing the company's global operations.

Significance

Sun Pharma is widely regarded as a flagship of the Indian pharmaceutical industry. Its acquisition of Ranbaxy Laboratories was one of the most significant consolidation events in Indian pharma history and elevated the combined entity's standing among the top generic drugmakers worldwide. The company is a constituent of major Indian equity indices and is closely tracked as a bellwether of the Indian pharmaceutical sector.

References